Schizophrenia Study for Participants on Clozapine
Summary
This study will look at how safe and how well the investigational drug NaBen®, in addition to clozapine, works in improving the symptoms of refractory schizophrenia.
Schizophrenia is a mental disorder consisting of positive symptoms, negative symptoms, and an inability to pay attention or process information clearly. Sodium benzoate has been shown to regulate brain chemicals that may help to improve some of the schizophrenia symptoms.
The active ingredient in the NaBen® tablet is sodium benzoate. Sodium benzoate is naturally found in cranberries, prunes, plums, cinnamon, ripe cloves, and apples.
Eligibility
Eligible gender: Male, Female
Eligible ages: 18 to 55
Inclusion criteria:
Male or female between 18-55 years of age.
Diagnosis of schizophrenia
Receiving clozapine
Has an identified caregiver or support person to assist with completing study rating scales.
Exclusion criteria:
Serious medical illnesses, epilepsy, head trauma, neurological illness, movement disorders.
Current substance abuse or history in the past 6 months
Certain medications as determined by the research team.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Psychopharmacology Research Unit (PRU) University of Calgary Mathison Centre for Mental Health Research & Education TRW Building, 1st floor 403-210-6904
Principal investigator:
Thomas Raedler
Clinical trial:
Yes
REB-ID:
REB17-1845